Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.12.2016 | short review | Ausgabe 4/2016

memo - Magazine of European Medical Oncology 4/2016

Treatment of chronic myelomonocytic leukemia

memo - Magazine of European Medical Oncology > Ausgabe 4/2016
MD Sonja Burgstaller


Since chronic myelomonocytic leukemia (CMML) has been classified within myelodysplastic syndromes (MDS) for a long time, most treatment data are derived from MDS trials. Owing to the limited number of CMML patients included in these trials, results are analyzed for the whole study population rather than for CMML patients as a distinct group. CMML patients with a myeloproliferative type of disease were often excluded. Therefore, generalization of data gained from MDS trials is very problematic. This review provides a brief overview of the treatment possibilities for patients with CMML. The paucity of existing clinical trials underlines the importance of including CMML patients into clinical studies whenever possible.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 4/2016

memo - Magazine of European Medical Oncology 4/2016 Zur Ausgabe